Detalles de la búsqueda
1.
Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks.
N Engl J Med
; 2024 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38819658
2.
BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children.
J Clin Immunol
; 43(3): 557-567, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36383294
3.
Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens.
J Clin Immunol
; 43(6): 1414-1425, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37160610
4.
Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.
Clin Exp Immunol
; 210(2): 91-103, 2022 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36208448
5.
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency.
J Clin Immunol
; 37(3): 301-310, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28316003
6.
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.
J Clin Immunol
; 37(6): 603-612, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28755067
7.
Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.
J Clin Immunol
; 36(6): 600-9, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27342758
8.
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease.
J Clin Immunol
; 36(6): 590-9, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27324887
9.
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
J Clin Immunol
; 36(7): 700-12, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27582171
10.
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
J Clin Immunol
; 36(6): 571-82, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27220317
11.
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
J Allergy Clin Immunol
; 130(4): 951-7.e11, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22846381
12.
Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency.
J Clin Immunol
; 37(6): 613, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28714047
13.
Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".
J Clin Immunol
; 37(8): 739-740, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28875256
14.
Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.
J Clin Immunol
; 32(4): 663-9, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22392046
15.
Neurologic manifestations of hereditary angioedema.
Ann Allergy Asthma Immunol
; 118(1): 119-120, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28007084
16.
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies.
Front Immunol
; 13: 1110388, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36605207
17.
Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease.
J Clin Immunol
; 31(3): 323-31, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21424824
18.
Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study.
Front Immunol
; 12: 632744, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33737935
19.
Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome.
J Child Adolesc Psychopharmacol
; 31(2): 118-128, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33601937
20.
Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm]).
Immunotherapy
; 13(10): 813-824, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33955240